Key Notes
- Lilly reported more than twice the average weight loss of Ozempic 2 mg with experimental retatrutide in an 80-week Phase 3 diabetes trial.
- LLY shares closed October 30 at $1,417.54, gaining 11.3% for the week alongside trial news, quarterly earnings and higher sales guidance.
- Retatrutide remains unapproved, with higher adverse-event discontinuations and a planned first-quarter 2027 regulatory filing among the next considerations.
Eli Lilly and Company (NYSE: LLY) has added a significant clinical result to its diabetes and obesity pipeline, reporting that experimental retatrutide produced more than twice the average weight loss of Ozempic 2 mg in a Phase 3 trial. The finding came during a strong week for Lilly shares that also included higher sales guidance.
LLY closed Friday, October 30, at $1,417.54, up approximately 3.2% on the day and 11.3% from the previous Friday, according to historical prices. American stock markets are closed on Sunday, so those figures describe the latest completed trading session.
The trial update was released on October 28, followed by Lilly’s quarterly results on October 29. The sequence matters: the week’s share-price advance coincided with both clinical progress and stronger commercial forecasts, rather than providing a clean measure of the trial’s individual market impact.
Retatrutide Delivered More Than Twice the Weight Loss
Lilly’s trial announcement reported the following average changes after 80 weeks in TRANSCEND-T2D-2:
- Retatrutide 9 mg: Weight fell 19.5%, or 20.1 kilograms, equivalent to 44.3 pounds.
- Retatrutide 12 mg: Weight fell 20.9%, or 21.5 kilograms, equivalent to 47.4 pounds.
- Ozempic 2 mg: Weight fell 9.4%, or 9.5 kilograms, equivalent to 20.9 pounds.
Both retatrutide doses reduced A1C by an average of 2.2 percentage points, compared with 1.8 points for Ozempic. A1C measures average blood glucose over roughly three months. Weight loss was a key secondary outcome; the primary endpoint concerned glucose control.
Ozempic is made by Novo Nordisk A/S (NYSE: NVO). This comparison used its highest approved injectable dose for type 2 diabetes. It was not a trial against every available obesity treatment or every semaglutide formulation.
The Study Has Important Design Limits
The trial registry identifies a randomized, open-label, multicenter study of adults with type 2 diabetes inadequately controlled with metformin, with or without an SGLT2 inhibitor. Lilly’s release put enrollment at 1,298 adults. Open-label means participants and investigators knew which treatment was assigned.
The reported results use an efficacy estimand: an analysis estimating outcomes if participants remained on treatment without starting additional glucose-lowering medication beyond the specified allowance. They should not be read as a promise that every patient prescribed the drug would achieve those results.
For investors, the distinction separates a strong controlled-trial signal from eventual routine use. Patient persistence, tolerability, the approved label and insurance coverage will influence the product’s commercial reach if it is authorized.
Side Effects Remain Part of the Assessment
Lilly reported gastrointestinal effects including diarrhea, nausea and vomiting. Treatment discontinuations due to adverse events were 4.8% with retatrutide 9 mg and 7.9% with 12 mg, compared with 2.7% for Ozempic.
The company said most reported events were mild to moderate. Detailed findings from this particular comparison are still intended for presentation at a medical meeting and publication in a peer-reviewed journal.
Retatrutide is a single molecule acting on GLP-1, GIP and glucagon receptors, according to Lilly’s drug explainer. That differs from semaglutide’s GLP-1 mechanism and from the dual GLP-1/GIP action of tirzepatide, sold by Lilly as Mounjaro and Zepbound.
The additional receptor target is a feature of the candidate’s biology, rather than a guarantee of superior overall safety or suitability for every patient. Regulatory review will consider the broader evidence alongside the weight-loss result.
LLY Shares Also Had an Earnings Catalyst
Lilly’s October 29 earnings release supplied an immediate commercial backdrop. Third-quarter revenue rose 39% to $24.4 billion, led by Mounjaro and Zepbound, while non-GAAP earnings reached $7.48 per share.
The company raised its 2026 revenue outlook to $91 billion–$92 billion from $85 billion–$87 billion. Its updated non-GAAP EPS range was $35–$36, below the previous $35.50–$36.50 range because acquired research charges more than offset an improvement in underlying earnings.
That combination helps explain why the financial picture cannot be reduced to one trial headline. Lilly is generating substantial sales from medicines already on the market, while investors also assign value to products still in development.
The stock gained approximately 6.6% on October 29 before Friday’s further advance. As we reported Friday, Lilly was among healthcare names reaching fresh intraday highs even as AI-related shares faced pressure.
We also previously covered Lilly’s move into the trillion-dollar valuation club. At that scale, future growth, realized drug prices and the cost of expanding supply remain central to how investors assess new clinical wins.
Approval and Commercial Execution Come Next
Retatrutide remains investigational and is not an approved medicine. Lilly’s September 29 program update set out a plan to submit a Biologics License Application to the Food and Drug Administration in the first quarter of 2027.
That is a filing target, rather than a confirmed approval or launch date. The October results add evidence to the development program without creating current retatrutide sales or settling its eventual price and reimbursement.
For LLY shareholders, the next milestones are the complete trial data, regulatory submission and review, and Lilly’s ability to turn its expanding metabolic portfolio into sustained earnings. The clinical result strengthens the pipeline story; execution will determine its financial contribution.
